Anti-SLPI antibody produced in rabbit

Description

• General description: Secretory leukocyte peptidase inhibitor (SLPI) is a serine-protease inhibitor which belongs to whey acidic protein family. The gene is mapped to human chromosome 20q13.12. It has four exons and encodes protein of molecular weight 11.7 kDa. It has whey-acidic-protein (WAP) motifs and the cysteine disulfide bond is crucial for its compact structure. It is secreted by epithelial cells and is present in saliva, cervical mucus and in seminal fluid.
• Immunogen: secretory leukocyte peptidase inhibitor recombinant protein epitope signature tag (PrEST)
• Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
• Biochem/physiol Actions: Secretory leukocyte peptidase inhibitor (SLPI) functions to protect tissues during inflammation. It inhibits human immunodeficiency virus 1 (HIV-1) infection by interacting with and modulating cluster of differentiation (CD4) lymphocytes. SLPI has antimicrobial property and regulates wound healing. It also interacts with β1 tubulin in platelets and regulates proteolysis. SLPI promotes carcinogenesis in lung cancer. Low expression of SLPI in nasopharyngeal epithelium promotes Epstein-Barr virus (EBV)-mediated nasopharyngeal carcinoma (NPC). SLPI is highly expressed in ovarian and pancreatic cancer.
• Features and Benefits: Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways:IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.Protein array of 364 human recombinant protein fragments.
• Linkage: Corresponding Antigen APREST86545
• Physical form: Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.
• Legal Information: Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.